Marinus Pharmaceuticals (MRNS) Posts Earnings Results, Misses Expectations By $0.06 EPS

Share on StockTwits

Marinus Pharmaceuticals (NASDAQ:MRNS) posted its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.06), MarketWatch Earnings reports.

Shares of MRNS stock traded down $0.04 during trading on Tuesday, reaching $4.83. The company had a trading volume of 13,482 shares, compared to its average volume of 814,209. Marinus Pharmaceuticals has a one year low of $3.31 and a one year high of $10.54. The company has a market capitalization of $203.84 million, a price-to-earnings ratio of -5.85 and a beta of 2.53.

A hedge fund recently raised its stake in Marinus Pharmaceuticals stock. Bank of New York Mellon Corp boosted its holdings in Marinus Pharmaceuticals Inc (NASDAQ:MRNS) by 190.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 106,560 shares of the biopharmaceutical company’s stock after buying an additional 69,863 shares during the period. Bank of New York Mellon Corp owned approximately 0.26% of Marinus Pharmaceuticals worth $754,000 as of its most recent SEC filing. Institutional investors and hedge funds own 63.68% of the company’s stock.

MRNS has been the subject of a number of recent research reports. Cantor Fitzgerald reaffirmed a “buy” rating and set a $19.00 price target on shares of Marinus Pharmaceuticals in a research note on Monday, September 17th. BidaskClub raised Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 30th. Mizuho reissued a “buy” rating and issued a $13.00 price objective on shares of Marinus Pharmaceuticals in a research note on Thursday, August 2nd. ValuEngine raised Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, October 16th. Finally, Zacks Investment Research raised Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, October 10th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Marinus Pharmaceuticals currently has an average rating of “Buy” and an average price target of $19.67.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.

See Also: Using the New Google Finance Tool

Earnings History for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply